On November 17, 10x Genomics, Inc. fell 4.02% in Regular Trading, trading around $53.535 per share, with turnover of $30.6552 million.
The move followed a market focus on post-earnings valuation pressure, as several firms lowered price targets and recent CEO share sales continued to weigh on sentiment, even after the company disclosed two autoimmune biomarker research collaborations.
Earlier this month, 10x Genomics, Inc. reported third-quarter EPS of negative $0.15, better than expectations for a loss of about $0.25 to $0.27, while revenue of $150.667 million exceeded estimates near $148 million. The company also raised full-year revenue guidance to $625 million-$635 million, above the roughly $620.8 million consensus. Even so, target prices were cut after the report, including UBS to $61 from $90, adding to pressure on the stock’s valuation framework.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments